by synergycap1 | Aug 8, 2017 | Bad Credit Loans, Bank Lending, Business Loans, Capital, Non-Bank Loans, Working Capital
People growing their own marijuana is a significant concern to Big Pharma. As state legalization of cannabis-derivatives spreads, the drug companies contemplating the potential of medical marijuana see a threat from both homegrown and professionally harvested...
by synergycap1 | Aug 8, 2017 | Bad Credit Loans, Bank Lending, Business Loans, Capital, Non-Bank Loans, Working Capital
Rose Leadem Online Editorial Assistant Jobs can be rollercoasters: one minute you’re stressed out then the next you’re happily trucking along. Insurance website Insurance Quotes recently surveyed more than 1,000 working Americans across different career...
by synergycap1 | Aug 8, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
President Donald Trump would like to interrupt his vacation to deliver the following message: Don’t call this a vacation. The president has decamped from Washington to his private golf club in central New Jersey. But he has repeatedly pushed back on the idea...
by synergycap1 | Aug 8, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Working Capital
Uber Technologies Inc. has passed new rules forbidding board members from contacting employees at the ride-hailing firm for assistance or information, a change that was sparked by the company’s former CEO trying to drum up support for a possible shareholder...
by synergycap1 | Aug 8, 2017 | Bad Credit Loans, Business Lending, Business Loans, Capital, Finance, Non-Bank Loans, Working Capital
A strong Swiss franc, one of the landmark byproducts of the eurozone debt crisis, appears finally to be unwinding. It is more significant than just being a foreign-exchange trade.
by synergycap1 | Aug 8, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
Shares of FibroGen are soaring more than 50 percent in pre-market trading Tuesday after the biotech reported positive study results for a potential blockbuster drug. The biotech company’s drug pamrevlumab, a treatment for fatal lung disease idiopathic pulmonary...
